Penny Stocks To Watch & More If You’re Concerned About Monkeypox
Are you concerned about monkeypox? Even if you’re not, you might be interested in taking advantage of the speculative environment in the stock market today. If so, having a list of penny stocks and higher-priced stocks to watch might be helpful. Since the onset of the monkeypox FOMO, we’ve followed several companies closely. In light of recent developments, we’ll give a quick rundown of some of the highlights of each company, so you know what you’re looking at.
[Learn More] Penny Stocks Trading for Beginners 
10 Top Monkeypox Stocks To Watch
- Chembio Diagnostics Inc. (NASDAQ: CEMI)
- Aethlon Medical (NASDAQ: AEMD)
- E-Home Household Service Holdings Ltd. (NASDAQ: EJH)
- Tonix Pharmaceuticals (NASDAQ: TNXP)
- Applied DNA (NASDAQ: APDN)
- Siga Technologies Inc. (NASDAQ: SIGA)
- Chimerix (NASDAQ: CMRX)
- GeoVax Labs, Inc. (NASDAQ: GOVX)
- Bavarian Nordic (OTC: BVNRY)
- NanoViricides Inc. (NYSEAMERICAN: NNVC)
Chembio Diagnostics Inc. (NASDAQ: CEMI)
Chembio (CEMI Stock Report) caught a massive surge in trading activity in the stock market this week. In a recent article, we discussed how a shift in focus might be turning attention to ancillary or “pick and shovel” monkeypox stocks. These are the testing, diagnostics, and preventative product companies in the niche.
The company offers point-of-care diagnostic services focused on infectious diseases. Chembio has explained that its DPP technology offers broad market applications beyond infectious disease, though there is not a direct link to monkeypox itself. With upcoming earnings this week, it will be interesting to see if Chembio comments on how it may (or may not) address the uptick in monkeypox cases.
Aethlon Medical (NASDAQ: AEMD)
Aethlon’s (AEMD Stock Report) pipeline of treatments focuses on organ-threatening diseases. Its Hemopurifier has been studied to fight COVID-19 variants that can impact the efficacy of certain vaccines. Unlike Chembio, there has been mention of monkeypox directly. Aethlon says that “pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include Chikungunya, Dengue and West Nile virus, and Vaccinia and Monkeypox, which serve as models for human Smallpox infection.”
Next week the company releases its next quarterly report along with a business conference call. So if AEMD stock is on your list, keep August 9th in mind and listen to see if they mention monkeypox treatment development.
E-Home Household Service Holdings Ltd. (NASDAQ: EJH)
E-Home Household (EJH Stock Report) traded higher since it released news on July 27th linking it to monkeypox. The company offers household services in China. Everything from housekeeping and nannying to elderly and hospital care fall in its basket of services. Late last month and this month, E-Home announced monkeypox-related news, placing it on the radar for some traders.
It reported that it would explore potential monkeypox treatment programs through Its subsidiary, Zhongrun (Fujian) Pharmaceutical Co., Ltd., which specializes in personal care products specific to Chinese medicine. As a follow-up, this week, E-Home reported that it would supply traditional Chinese medicine herbs for potential monkeypox treatment programs.
Wenshan Xie, Chairman, and CEO of E-Home, explained, “Though there’s no treatment specifically for monkeypox virus, it shares similar symptoms to the more common smallpox virus, such as fever, muscle aches, and headaches, which TCM treatments have proven records of effectiveness in alleviating some of the symptoms. We hope to speed up and improve our studies so that we could deliver meaningful clinical outcome in the short future, bringing our vision for big health business to the next level.”
Tonix Pharmaceuticals (NASDAQ: TNXP)
Tonix Pharmaceuticals (TNXP Stock Report) made an explosive move during early afternoon trading on Thursday. The company’s infectious disease pipeline includes a vaccine to prevent smallpox and monkeypox called TNX-801. Tonix has already announced a new collaboration with the Kenya Medical Research Institute for developing TNX-801 and a Phase 1 clinical study could begin during the first half of 2023, according to a July PR.
With this link to a potential monkeypox treatment, TNXP stock has found itself on the list of penny stocks to watch.
Applied DNA (NASDAQ: APDN)
A former penny stock, Applied DNA (APDN Stock Report), helped wake up the small-cap market this week following a massive surge from under $1 to over $6.90 in just a few days. The epic move came after the company announced the start of the analytical validation of a PCR-based monkeypox virus test. If it gets validated, the company has plans to submit a package to the New York State Department of Health for approval.
Even a $12 million upsized offering at $4 hasn’t shaken investors hunting for monkeypox stocks. Accordingly, Applied DNA stated that it intends to use the net proceeds from this offering for further development of its Therapeutic DNA Production and MDx Testing Services, among other things, including potential acquisitions.
Siga Technologies Inc. (NASDAQ: SIGA)
What may have become one of the forerunners of monkeypox stocks, Siga Technologies (SIGA Stock Report), has remained red hot for months. What began as speculation in May has turned into a much longer-term trend for SIGA stock. It boils down to the company’s TPOXX smallpox treatment. Thanks to the correlation between the virus and monkeypox, the company has been one of the most popular names discussed.
[Read More] 5 Penny Stocks To Buy For Under $5
According to Reuters, what has also helped is reports that the Department of Defense recently bought more doses of TPOXX from Siga to maintain a stockpile for treatment against smallpox. With new mandates in New York, Illinois, and California declaring a state of emergency, SIGA stock and others are gaining ground in the stock market today.
Chimerix (NASDAQ: CMRX)
Chimerix (CMRX Stock Report) is somewhat of a unique monkeypox stock to watch. Emergent BioSolutions Inc. (NYSE: EBS) previously bought exclusive worldwide rights to Chimerix’s Tembexa. The treatment is the first FDA-approved antiviral for all age groups for smallpox. In a May update, Paul Williams, SVP government/MCM business at Emergent, explained, “This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government’s smallpox preparedness strategy.”
There’s a 20% royalty on future gross profit in the US based on volume milestones above 1.7 million doses. It could also give Chimerix a 15% royalty on all gross profit outside of the US on a market-to-market basis. Chimerix will present at the Wedbush PacGrow Healthcare Conference next week. So if CMRX stock is on your radar, keep August 9th in mind.
GeoVax Labs, Inc. (NASDAQ: GOVX)
Like Siga, GeoVax (GOVX Stock Report) is somewhat of a bellwether for lower-priced monkeypox stocks. Shares were trading below $1 on July 22nd and managed to reach highs of $4.30 leading up to this week.
GeoVax’s GV-MVA-VLPTM platform can construct vaccine candidates using genetic sequences from viruses. A statement earlier this year has come to focus thanks to GeoVax’s Chief Scientific Officer, Farshad Guirakhoo, Ph.D.:
“Perhaps of critical importance is that the viral basis of our vaccine vector (MVA) has more than 50 years of safety records and has been recently approved by the FDA for prevention of smallpox and monkeypox diseases.”
In an earnings update this week, management spoke on the monkeypox threat. “Currently, evaluation is underway related to GEO-CM04S1 and the prevention of Monkeypox. The results are anticipated to demonstrate successful protection, validating that GEO-CM04S1 is protective against both COVID-19 and Monkeypox. GeoVax also anticipates validating its hemorrhagic fever virus vaccines as protective against Monkeypox, potentially providing unique vaccines preventing both hemorrhagic fever virus and Monkeypox virus in a single vaccine.”
Bavarian Nordic (OTC: BVNRY)
What might have been one of the most under-discussed monkeypox stocks so far is Bavarian Nordic (BVNRY Stock Report). When the World Health Organization declared the monkeypox outbreak a global health emergency, the company obtained an expanded European label for its smallpox vaccine JYNNEOSTM (also known by the brand names Imvamune and Imvanex), to include the monkeypox virus.
It also obtained orders for the JYNNEOS® smallpox vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA). This would allow for the first doses of this version to be manufactured and invoiced in 2023 and 2024.
According to headlines this week, the options have a value of $119 million and “represent the first options exercised to convert bulk vaccine…into freeze-dried doses of JYNNEOS smallpox vaccine.”
NanoViricides Inc. (NYSEAMERICAN: NNVC)
Recently, a company that developed drugs to combat things like pediatric hepatitis has come into focus. NanoViricides (NNVC Stock Report) works on antiviral therapies based on its “nanomedicines” platform. In addition to hepatitis, NanoViricides has also begun human trials of a SARS-CoV-2 drug candidate for COVID 19. So why is it on a list of monkeypox stocks?
This week it announced that it began drug development to combat the monkeypox virus. “We are excited to act rapidly to develop much needed, safe and effective monkeypox therapeutics,” said Anil R. Diwan , Ph.D., President of the Company. “We are confident of developing a strong drug to treat the monkeypox virus infection, based on our recent successes in developing clinic-worthy drugs against human coronaviruses (including SARS-CoV-2 variants that have continued the evolution of COVID-19 global pandemic) as well as Shingles.”
With this news, NNVC has now become one of the potential monkeypox stocks to watch this week.
A Presidential Catalyst For Monkeypox Stocks
This new niche has become a popular one for speculators. Keeping an eye on significant headlines, both good and bad, will help when it comes to gauging sentiment. This week President Biden was said to be weighing a health emergency for monkeypox.
Reports from the Washington Post have already highlighted that the Administration plans to declare the outbreak a public health emergency to substantiate awareness and increase access to funding to fight the spread. So far, this has helped the broader trend. The question is, how long will it last, and what will be the next headline to add more volatility to monkeypox stocks?